Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE–TIMI 60 trial
- 1 January 2022
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 243, 147-157
Abstract
No abstract availableKeywords
Funding Information
- Amgen
- Bayer Fund
- Novartis
- Bristol-Myers Squibb
- Eisai
- Roche
- Pfizer
- MedImmune
- Takeda Pharmaceutical Company
- AstraZeneca
- Servier
- Janssen Pharmaceutica
- Abbott Laboratories
- Swedish Orphan Biovitrum
- Medicines Company
- Merck
- Boehringer Ingelheim
- GlaxoSmithKline
This publication has 40 references indexed in Scilit:
- Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]The American Journal of Cardiology, 2013
- Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or PneumoniaJAMA, 2013
- Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction TrialsCirculation: Cardiovascular Quality and Outcomes, 2012
- High-Sensitivity C-Reactive Protein Is Within Normal Levels at the Very Onset of First ST-Segment Elevation Acute Myocardial Infarction in 41% of CasesJACC, 2011
- The p38 mitogen-activated protein kinase pathway—A potential target for intervention in infarction, hypertrophy, and heart failureJournal of Molecular and Cellular Cardiology, 2011
- Usefulness of Serial Assessment of B-Type Natriuretic Peptide, Troponin I, and C-Reactive Protein to Predict Left Ventricular Remodeling After Acute Myocardial Infarction (from the REVE-2 Study)The American Journal of Cardiology, 2010
- Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)The American Journal of Cardiology, 2010
- Inflammatory Markers and Incident Heart Failure Risk in Older AdultsJACC, 2010
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Role of p38? MAPK in cardiac apoptosis and remodeling after myocardial infarctionJournal of Molecular and Cellular Cardiology, 2005